AHA.13 offers 20 late-breaking trials

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon
 - Dallas

The American Heart Association (AHA) unveiled its lineup of 2013 late-breaking clinical trials to be presented Nov. 17-19 at its scientific sessions in Dallas. The program also will include 19 special reports.

The full conference will run Nov. 16-20. The schedule for late-breakers is listed below.

Sunday, Nov. 17

  • Nitrites in Acute Myocardial Infarction, an assessment of the efficacy of sodium nitrate to reduce MI in STEMI patients
  • Blood Pressure Reduction Among Acute Ischemic Stroke Patients: A Randomized Controlled Clinical Trial
  • Randomized Clinical Trial of Pre-hospital Induction of Mild Hypothermia in Out-of-Hospital Cardiac Arrest Patients Using a Rapid Infusion of 4oC Normal Saline, to assess outcomes from early field cooling in resuscitated cardiac arrest patients
  • Target Temperature Management 33°C versus 36°C after Out-of-hospital Cardiac Arrest, a Randomized, Parallel Group, Assessor Blinded Clinical Trial

Monday, Nov. 18

  • Promotion of Cardiovascular Health in Preschool Children: 36-month Cohort Follow-up, an educational intervention promoting healthy eating and an active lifestyle for preschoolers
  • Randomized Trial of Social Network Lifestyle Intervention for Obesity: MICROCLINIC Intervention Results and 16-Month Follow-up, a weight-loss intervention
  • Multifaceted Intervention to Improve Medication Adherence and Secondary Prevention Measures (Medication Study) After Acute Coronary Syndrome Hospital Discharge
  • China Rural Health Initiative - Sodium Reduction Study: the Effects of a Community-Based Sodium Reduction Program on 24hr Urinary Sodium and Blood Pressure in Rural China, a cluster randomized trial
  • Atrial Antitachycardia Pacing and Managed Ventricular Pacing Reduce the Endpoint Composed by Death, Cardiovascular Hospitalizations and Permanent Atrial Fibrillation Compared to Conventional Dual Chamber Pacing in Bradycardia Patients: Results of the Minerva Randomized Study
  • Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) Trial, a study to determine if adding low-dose dopamine or low-dose nesiritide to diuretic dosing improves decongestion in acute heart failure patients
  • Severe Ischemic Mitral Regurgitation: Is it Better to Repair or Replace the Valve
  • Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT), a placebo-controlled study to assess spironolactone, an aldosterone antagonist, in heart failure patients with preserved cardiac function
  • One Year Mortality in STEMI Patients Randomized to Primary PCI or a Pharmaco-invasive Strategy. The Stream 1 Year Follow-up
  • Secretory Phospholipase A2 Inhibition with Varespladib and Cardiovascular Events in Patients with an Acute Coronary Syndrome: Results of the VISTA-16 Study
  • Randomized Comparison of Endovascular Revascularization Plus Supervised Exercise Therapy Versus Supervised Exercise Therapy Only in Patients with Peripheral Artery Disease and Intermittent Claudication: Results of the Endovascular Revascularization and Supervised Exercise (ERASE) Trial
  • A Randomized Multicenter Clinical Trial of Renal Artery Stenting in Preventing Cardiovascular and Renal Events: Results of the CORAL Study: An evaluation of renal artery stenting vs. medical therapy alone in patients with atherosclerotic renal artery stenosis

Tuesday, Nov. 19

  • RADAR-AF Trial. A Randomized Multicenter Comparison of Radiofrequency Catheter Ablation of Drivers versus Circumferential Pulmonary Vein Isolation in Patients with Atrial Fibrillation, an evaluation of the safety and efficacy in radiofrequency catheter ablation as a therapy for atrial fibrillation
  • A Randomized Trial Comparing Genotype-Guided Dosing of Warfarin to Standard Dosing: The EU Pharmacogenetics of Anticoagulant Therapy (EU-PACT) Warfarin Study
  • The Clarification of Optimal Anticoagulation through Genetics (COAG) trial
  • ENGAGE AF-TIMI 48 Primary Results, a randomized, controlled clinical trial comparing the clinical efficacy and safety of two doses of the novel oral anticoagulant edoxaban with warfarin in patients with atrial fibrillation